Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Export metadata

Statistics

Number of document requests

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen, Leo M. A. Heunks, Bruno Mourvillier, Sanne de Bruin, Endry H. T. Lim, Matthijs C. Brouwer, Pieter R. Tuinman, José F. K. Saraiva, Gernot Marx, Suzana M. Lobo, Rodrigo Boldo, Jesus A. Simon-Campos, Alexander D. Cornet, Anastasia Grebenyuk, Johannes M. Engelbrecht, Murimisi Mukansi, Philippe G. Jorens, Robert Zerbib, Simon Rückinger, Korinna Pilz, Renfeng Guo, Diederik van de Beek, Niels C. Riedemann, Ulrich Jaschinski
Frontdoor URLhttps://opus.bibliothek.uni-augsburg.de/opus4/100922
ISSN:2213-2600OPAC
Parent Title (English):The Lancet Respiratory Medicine
Publisher:Elsevier
Type:Article
Language:English
Year of first Publication:2022
Release Date:2023/01/17
Tag:Pulmonary and Respiratory Medicine
Volume:10
Issue:12
First Page:1137
Last Page:1146
Note:
Ulrich Jaschinski is a member of the PANAMO Investigators. Please see the publisher's website for a complete authors list.
DOI:https://doi.org/10.1016/s2213-2600(22)00297-1
Institutes:Medizinische Fakultät
Medizinische Fakultät / Universitätsklinikum
Medizinische Fakultät / Lehrstuhl für Anästhesiologie und Operative Intensivmedizin